QIAGEN Teams Up with NVIDIA to Advance AI-Driven Drug Discovery

Shots: QIAGEN to integrate its Digital Insights bioinformatics business with NVIDIA accelerated computing & the NVIDIA BioNeMo platform to strengthen AI applications in drug discovery Partnership leverages graph-based AI that apply retrieval & reasoning techniques across biomedical knowledge graphs to help researchers analyze complex biological data & validate AI-generated insights, supporting practical applications across the…

ByRidhi RastogiMay 20, 2026

NEWS

Hansa Biopharma Grants European and MENA rights of Idefirix to SERB Pharmaceuticals in a €115M Deal

Shots: Hansa has granted SERB exclusive development & commercialisation rights to Idefirix (imlifidase) in the EU, UK, Switzerland, Norway, Liechtenstein, Iceland & the MENA region As per the deal, Hansa will receive €110M upfront & an additional €5M upon acceptance of the full approval filing for Idefirix by the EMA. Hansa will also support SERB in…

ByRidhi RastogiMay 19, 2026

NEWS

Regeneron Inks a ~$2.3B Deal with Parabilis Medicines to Advance Antibody-Helicon Conjugates Across Multiple Therapeutic Areas

Shots: Regeneron has entered a strategic research collaboration with Parabilis to discover & develop multiple therapeutics using Parabilis’ Helicon peptide platform, with a focus on Antibody-Helicon Conjugates (AHCs) Regeneron will lead development, manufacturing, & global commercialization, while Parabilis will receive $125M, incl. $50M upfront & a $75M commitment toward its next equity financing, subject to…

ByRidhi RastogiMay 18, 2026

NEWS

Fosun Pharma Obtains Option on AriBio’s Alzheimer’s Disease (AD) Therapy AR1001

Shots: Fosun Pharma & AriBio have entered into an exclusive global option agreement for the development, registration, manufacturing, & commercialization of AR1001 for AD, expanding their partnership beyond Greater China & 10 ASEAN countries AriBio will receive a $60M option fee & retain the right to exercise the option within the agreed period, while Fosun…

ByRidhi RastogiMay 14, 2026

NEWS

Isomorphic Labs Raises $2.1B in Series B Funding to Scale AI Drug Design Engine & Advance Pipeline

Shots: Isomorphic Labs has reported a $2.1B Series B financing round led by Thrive Capital, with participation from existing investors Alphabet & GV alongside new backers MGX, Temasek, CapitalG, & the UK Sovereign AI Fund The company plans to use the capital to further develop & deploy its AI-powered drug discovery platform, IsoDDE, accelerate internal…

ByRidhi RastogiMay 13, 2026

NEWS

Boehringer Ingelheim Inks ~$ 479.6M Deal with Immunitas Therapeutics for a Preclinical Antibody Program

Shots: BI has entered into a global licensing agreement with Immunitas for a preclinical antibody program being developed for chronic inflammatory & autoimmune diseases As per the deal, BI will obtain global rights to develop, manufacture, & commercialize the antibody program in exchange for an upfront payment, up to €407.5M (~$479.6M) in development, regulatory, &…

ByRidhi RastogiMay 13, 2026

INSIGHTS+

The US FDA New Drug Approvals in April 2026

Shots: Approval activity continued strongly into April 2026, with the US FDA authorizing two significant therapies across metabolic disease and infectious disease, reinforcing the agency’s focus on chronic disease management, long-term treatment innovation, and broader patient access. Two notable therapies achieved regulatory clearance: Eli Lilly’s Foundayo for weight loss in obese or overweight adults with weight-related conditions,…

ByDipanshu DixitMay 12, 2026

NEWS

Rigel Signs ~$445M Licensing Pact with Arvinas and Pfizer for Veppanu

Shots: Rigel has entered into an exclusive, global license agreement with Arvinas & Pfizer to develop, manufacture & commercialize FDA-approved Veppanu (vepdegestrant) for ER+/HER2-, ESR1-mutated advanced or metastatic breast cancer. As per the deal, Rigel will pay Arvinas & Pfizer $70M upfront, $15M in upon completion of transition activities, & ~$320M in milestones plus tiered royalties…

ByRidhi RastogiMay 12, 2026

NEWS

GSK Collaborates with Sino Biopharmaceutical to Accelerate Bepirovirsen at Launch

Shots: GSK has entered an exclusive strategic collaboration with Sino Biopharmaceutical, via its subsidiary CTTQ, to support the launch & commercialization of bepirovirsen (under NMPA’s priority review) in mainland China CTTQ will manage importation, distribution, hospital access, and promotional & non-promotional activities in China under a 5.5yr. supply deal with GSK On the other hand,…

ByRidhi RastogiMay 11, 2026

NEWS

GSK Partners with Halozyme to Develop SC Formulation of Multiple Oncology Drugs

Shots: GSK has entered into a global collaboration & license agreement with Halozyme to develop & commercialize SC formulation of multiple oncology targets, incl. ADCs, as well as an option for additional future drug targets As per the deal, GSK will license Enhanze drug delivery tech from Halozyme in exchange of upfront payment, as well…

ByRidhi RastogiMay 8, 2026

QIAGEN Teams Up with NVIDIA to Advance AI-Driven Drug Discovery

Hansa Biopharma Grants European and MENA rights of Idefirix to SERB Pharmaceuticals in a €115M Deal

Regeneron Inks a ~$2.3B Deal with Parabilis Medicines to Advance Antibody-Helicon Conjugates Across Multiple Therapeutic Areas

Fosun Pharma Obtains Option on AriBio’s Alzheimer’s Disease (AD) Therapy AR1001

Isomorphic Labs Raises $2.1B in Series B Funding to Scale AI Drug Design Engine & Advance Pipeline

Boehringer Ingelheim Inks ~$ 479.6M Deal with Immunitas Therapeutics for a Preclinical Antibody Program

The US FDA New Drug Approvals in April 2026

Rigel Signs ~$445M Licensing Pact with Arvinas and Pfizer for Veppanu

GSK Collaborates with Sino Biopharmaceutical to Accelerate Bepirovirsen at Launch

GSK Partners with Halozyme to Develop SC Formulation of Multiple Oncology Drugs

Contact US

FOLLOW US